Modera Wealth Management LLC Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Modera Wealth Management LLC trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,299 shares of the medical equipment provider’s stock after selling 197 shares during the period. Modera Wealth Management LLC’s holdings in Zimmer Biomet were worth $771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. CKW Financial Group raised its holdings in shares of Zimmer Biomet by 11.7% in the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares in the last quarter. FWG Holdings LLC boosted its holdings in shares of Zimmer Biomet by 2.9% in the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock valued at $372,000 after acquiring an additional 101 shares during the last quarter. Romano Brothers AND Company boosted its holdings in Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock worth $1,000,000 after buying an additional 102 shares in the last quarter. Dakota Wealth Management boosted its holdings in Zimmer Biomet by 1.3% during the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock worth $1,016,000 after buying an additional 122 shares in the last quarter. Finally, Creative Financial Designs Inc. ADV boosted its holdings in Zimmer Biomet by 23.6% during the third quarter. Creative Financial Designs Inc. ADV now owns 771 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 147 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $103.98 on Wednesday. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The stock has a market cap of $20.70 billion, a P/E ratio of 23.37, a PEG ratio of 1.95 and a beta of 1.02. The company has a 50-day moving average price of $105.63 and a 200 day moving average price of $107.28. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company earned $2.20 earnings per share. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Analyst Ratings Changes

A number of equities analysts have weighed in on ZBH shares. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Raymond James reduced their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Truist Financial restated a “hold” rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.